{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:19:40Z","timestamp":1788621580768,"version":"build-2803163510"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:00:00Z","timestamp":1746316800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Fingolimod (FTY720) was the first sphingosine-1-phosphate (S1P) receptor modulator approved by the US Food and Drug Administration for the treatment of multiple sclerosis. The active form, FTY720 (S)-P, acts as a potent agonist of the S1P receptor, leading to its downregulation on the cell surface, reduced activity, and termination of sphingosine-dependent intracellular signalling. Elevated hepatic enzyme levels, clinically significant liver injury, and acute liver failure have been observed in patients treated with FTY720 (S)-P, which requires additional monitoring. This is the first study to investigate the mechanisms underlying the hepatotoxicity of FTY720 (S)-P and represents an important contribution to elucidating its toxicity mechanisms in the human hepatocellular carcinoma cell line HepG2. Following a 72-h exposure, standard methods were used to evaluate specific targets, including cytotoxic effect potentials, mitochondrial parameters, and changes of the antioxidant enzyme levels. FTY720 (S)-P exposure resulted in time- and dose-dependent decreases in cell viability, mitochondrial membrane potential, and ATP levels, as well as the induction of oxidative stress. The complex toxic profile observed for FTY720 (S)-P is hypothesized to originate from its interaction with sirtuin proteins, particularly SIRT3 and SIRT5. It was also complemented with molecular docking simulations to assess the compound's targeting potential by analysing its interaction profile and binding pose within the active sites of both proteins. The results supported the proposed hypothesis, demonstrating an optimal fitting profile and favourable interaction behaviour within the binding pockets of the SIRT3 and SIRT5 enzymes.<\/jats:p>","DOI":"10.1093\/toxres\/tfaf064","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T16:36:39Z","timestamp":1746376599000},"source":"Crossref","is-referenced-by-count":3,"title":["In vitro investigation of the toxicological mechanisms of Fingolimod (S)-phosphate in HEPG2 cells"],"prefix":"10.1093","volume":"14","author":[{"given":"Ay\u015fenur","family":"Bilgehan","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul University , Fatih, Istanbul 34116 ,","place":["T\u00fcrkiye"]},{"name":"Institute of Graduate Studies in Health Sciences, Istanbul University , Fatih, Istanbul 34116 ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"\u015eeker","sequence":"additional","affiliation":[{"name":"Institute of Graduate Studies in Health Sciences, Istanbul University , Fatih, Istanbul 34116 ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed T","family":"Qaoud","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Department of Pharmacy, Cyprus International University , Nicosia, Northern Cyprus 99258 ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-5723","authenticated-orcid":false,"given":"G\u00fcl","family":"\u00d6zhan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Department of Pharmaceutical Toxicology, Istanbul University , Fatih, Istanbul 34116 ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,4]]},"reference":[{"key":"2025050510564173500_ref1","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"2025050510564173500_ref2","volume-title":"Types of MS","author":"National Multiple Sclerosis Society"},{"key":"2025050510564173500_ref3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clim.2011.05.005","article-title":"Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy","volume":"142","author":"Ingwersen","year":"2012","journal-title":"Clin Immunol"},{"key":"2025050510564173500_ref4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17460441.2019.1646244","article-title":"Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis","volume":"14","author":"Volpi","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"2025050510564173500_ref5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41429-020-0351-0","article-title":"Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii","volume":"73","author":"Chiba","year":"2020","journal-title":"J Antibiot"},{"key":"2025050510564173500_ref6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"2025050510564173500_ref7","volume-title":"Clinical and research information on drug-induced liver injury [internet]","author":"LiverTox","year":"2012"},{"key":"2025050510564173500_ref8","doi-asserted-by":"publisher","first-page":"4397159","DOI":"10.1155\/2018\/4397159","article-title":"More than just an immunosuppressant: the emerging role of FTY720 as a novel inducer of ROS and apoptosis","volume":"2018","author":"Takasaki","year":"2018","journal-title":"Oxidative Med Cell Longev"},{"key":"2025050510564173500_ref9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"2025050510564173500_ref10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/bcp.14198","article-title":"The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: a meta-analysis","volume":"86","author":"Yang","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2025050510564173500_ref11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1212\/CPJ.0b013e31823c51dd","article-title":"Fingolimod","volume":"1","author":"Hyland","year":"2011","journal-title":"Neurol Clin Pract"},{"key":"2025050510564173500_ref12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.15698\/mic2017.12.601","article-title":"A genome-wide screen for FTY720-sensitive mutants reveals genes required for ROS homeostasis","volume":"4","author":"Hagihara","year":"2017","journal-title":"Microbial Cell (Graz, Austria)"},{"key":"2025050510564173500_ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines9010012","article-title":"Safety of newer disease modifying therapies in multiple sclerosis","volume":"9","author":"Jalkh","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2025050510564173500_ref14","volume-title":"Highlights of prescribing information","author":"FDA","year":"2010"},{"key":"2025050510564173500_ref15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"2025050510564173500_ref16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/organoids3020008","article-title":"Development and optimization of a lactate dehydrogenase assay adapted to 3D cell cultures","volume":"3","author":"Castiglione","year":"2024","journal-title":"Organ"},{"key":"2025050510564173500_ref17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat Protoc"},{"key":"2025050510564173500_ref18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/0471142956.cy0914s13","article-title":"Flow cytometric analysis of mitochondrial membrane potential using JC-1","volume":"13","author":"Cossarizza","year":"2000","journal-title":"Curr Protoc Cytom"},{"key":"2025050510564173500_ref19","doi-asserted-by":"publisher","first-page":"12246","DOI":"10.1007\/s11356-016-6450-6","article-title":"Tetrabromobisphenol a (TBBPA)-stimulated reactive oxygen species (ROS) production in cell-free model using the 2\u2032,7\u2032-dichlorodihydrofluorescein diacetate (H2DCFDA) assay-limitations of method","volume":"23","author":"Szychowski","year":"2016","journal-title":"Environ Sci Pollut Res"},{"key":"2025050510564173500_ref20","first-page":"882","article-title":"Improved method for the determination of blood glutathione","volume":"61","author":"Beutler","year":"1963","journal-title":"J Lab Clin Med"},{"key":"2025050510564173500_ref21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13065-024-01207-1","article-title":"Synthesis of novel carbazole hydrazine-carbothioamide scaffold as potent antioxidant, anticancer and antimicrobial agents","volume":"18","author":"\u00c7apan","year":"2024","journal-title":"BMC Chem"},{"key":"2025050510564173500_ref22","doi-asserted-by":"publisher","first-page":"29512","DOI":"10.1021\/acsomega.3c03256","article-title":"New thiazole carboxamide derivatives as COX inhibitors: design, synthesis, anticancer screening, in silico molecular docking, and ADME profile studies","volume":"8","author":"Hawash","year":"2023","journal-title":"ACS Omega"},{"key":"2025050510564173500_ref23","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/covid4060046","article-title":"Computational discovery of novel imidazole derivatives as inhibitors of SARS-CoV-2 main protease: an integrated approach combining molecular dynamics and binding affinity analysis","volume":"4","author":"Babalola","year":"2024","journal-title":"COVID"},{"key":"2025050510564173500_ref24","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J Med Chem"},{"key":"2025050510564173500_ref25","doi-asserted-by":"publisher","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucl Acid Res"},{"key":"2025050510564173500_ref26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"2025050510564173500_ref27","doi-asserted-by":"publisher","first-page":"807639","DOI":"10.3389\/fphar.2022.807639","article-title":"Molecular pharmacology and novel potential therapeutic applications of fingolimod","volume":"13","author":"Pournajaf","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025050510564173500_ref28","doi-asserted-by":"publisher","first-page":"11397","DOI":"10.1021\/acs.jmedchem.0c00524","article-title":"Drug induced liver injury (DILI). Mechanisms and medicinal chemistry avoidance\/mitigation strategies","volume":"63","author":"Norman","year":"2020","journal-title":"J Med Chem"},{"key":"2025050510564173500_ref29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/toxsci\/65.2.166","article-title":"Mechanisms of hepatotoxicity","volume":"65","author":"Jaeschke","year":"2002","journal-title":"Toxicol Sci"},{"key":"2025050510564173500_ref30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ejps.2011.12.014","article-title":"Autophagy induced by FTY720 promotes apoptosis in U266 cells","volume":"45","author":"Liao","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"2025050510564173500_ref31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.toxlet.2015.04.015","article-title":"FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells","volume":"236","author":"Zhang","year":"2015","journal-title":"Toxicol Lett"},{"key":"2025050510564173500_ref32","doi-asserted-by":"publisher","first-page":"81907","DOI":"10.1371\/journal.pone.0081907","article-title":"Fingolimod (FTY720) stimulates Ca2+\/calcineurin signaling in fission yeast","volume":"8","author":"Hagihara","year":"2013","journal-title":"PLoS One"},{"key":"2025050510564173500_ref33","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.4161\/auto.6.8.13614","article-title":"FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy","volume":"6","author":"Zhang","year":"2010","journal-title":"Autophagy"},{"key":"2025050510564173500_ref34","doi-asserted-by":"publisher","first-page":"e00171","DOI":"10.1002\/prp2.171","article-title":"FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity","volume":"3","author":"Ahmed","year":"2015","journal-title":"Pharma Res Per"},{"key":"2025050510564173500_ref35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/gtc.12134","article-title":"FTY720 stimulated ROS generation and the Sty1\/Atf1 signaling pathway in the fission yeast Schizosaccharomyces pombe","volume":"19","author":"Hagihara","year":"2014","journal-title":"Genes Cells"},{"key":"2025050510564173500_ref36","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","article-title":"Activation of apoptosis signalling pathways by reactive oxygen species","volume":"1863","author":"Redza-Dutordoir","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"2025050510564173500_ref37","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-3-642-00663-0_11","article-title":"Mitochondrial involvement in drug-induced liver injury","volume":"196","author":"Pessayre","year":"2010","journal-title":"Handb Exp Pharmacol"},{"key":"2025050510564173500_ref38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10010034","article-title":"Neuronal metabolism and neuroprotection: neuroprotective effect of fingolimod on menadione-induced mitochondrial damage","volume":"10","author":"Gil","year":"2020","journal-title":"Cells"},{"key":"2025050510564173500_ref39","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2019.04.022","article-title":"The S1P mimetic fingolimod phosphate regulates mitochondrial oxidative stress in neuronal cells","volume":"137","author":"Mart\u00edn-Monta\u00f1ez","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"2025050510564173500_ref40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.18231\/j.ijcaap.2022.003","article-title":"Basics, types and applications of molecular docking: a review","volume":"7","author":"Raval","year":"2022","journal-title":"IJCAAP"},{"key":"2025050510564173500_ref41","doi-asserted-by":"publisher","first-page":"e38173","DOI":"10.1016\/j.heliyon.2024.e38173","article-title":"Bioinformatics analysis based on extracted ingredients combined with network pharmacology, molecular docking and molecular dynamics simulation to explore the mechanism of jinbei oral liquid in the therapy of idiopathic pulmonary fibrosis","volume":"10","author":"Han","year":"2024","journal-title":"Heliyon"},{"key":"2025050510564173500_ref42","volume-title":"Application of computer-based methods to guide the development of novel sirtuin inhibitors","author":"Karaman","year":"2015"},{"key":"2025050510564173500_ref43","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1096\/fj.13-245241","article-title":"SIRT5 is under the control of PGC-1\u03b1 and AMPK and is involved in regulation of mitochondrial energy metabolism","volume":"28","author":"Buler","year":"2014","journal-title":"FASEB J"},{"key":"2025050510564173500_ref44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1101\/sqb.2011.76.010629","article-title":"Sirtuins, aging, and metabolism","volume":"76","author":"Guarente","year":"2011","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"2025050510564173500_ref45","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1089\/ars.2017.7290","article-title":"The role of sirtuins in antioxidant and redox signaling","volume":"28","author":"Singh","year":"2018","journal-title":"Antioxid Redox Signal"},{"key":"2025050510564173500_ref46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature08778","article-title":"SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation","volume":"464","author":"Hirschey","year":"2010","journal-title":"Nature"},{"key":"2025050510564173500_ref47","doi-asserted-by":"publisher","first-page":"e11707","DOI":"10.1371\/journal.pone.0011707","article-title":"Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis","volume":"5","author":"Kong","year":"2010","journal-title":"PLoS One"},{"key":"2025050510564173500_ref48","doi-asserted-by":"publisher","first-page":"9580","DOI":"10.1021\/acs.jmedchem.2c00687","article-title":"Therapeutic potential and activity modulation of the protein lysine deacylase sirtuin 5","volume":"65","author":"Fiorentino","year":"2022","journal-title":"J Med Chem"},{"key":"2025050510564173500_ref49","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.cell.2009.02.026","article-title":"SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle","volume":"137","author":"Nakagawa","year":"2009","journal-title":"Cell"},{"key":"2025050510564173500_ref50","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.molcel.2013.06.001","article-title":"SIRT5-mediated lysine desuccinylation impacts diverse metabolic pathways","volume":"50","author":"Park","year":"2013","journal-title":"Mol Cell"},{"key":"2025050510564173500_ref51","doi-asserted-by":"publisher","DOI":"10.1201\/9781420042061","volume-title":"Toxicology: a case-oriented approach","author":"Fenton","year":"2001","edition":"1st ed."},{"key":"2025050510564173500_ref52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.18053\/jctres.04.201801.005","article-title":"Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives","volume":"4","author":"Ramachandran","year":"2018","journal-title":"J Clin Transl Res"},{"key":"2025050510564173500_ref53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.toxicon.2019.11.009","article-title":"Molecular docking and mechanisms of fusaric acid induced mitochondrial sirtuin aberrations in glycolytically and oxidatively poised human hepatocellular carcinoma (HepG2) cells","volume":"173","author":"Abdul","year":"2020","journal-title":"Toxicon"},{"key":"2025050510564173500_ref54","doi-asserted-by":"publisher","first-page":"10165","DOI":"10.1080\/07391102.2023.2256402","article-title":"Identification of novel scaffolds targeting SIRT3 through molecular modeling techniques for the treatment of hepatocellular carcinoma","volume":"42","author":"Maya Ram\u00edrez","year":"2024","journal-title":"J Biomol Struct Dyn"},{"key":"2025050510564173500_ref55","doi-asserted-by":"publisher","first-page":"36214","DOI":"10.1039\/C7RA05824A","article-title":"Interactions between sirtuins and fluorogenic small-molecule substrates offer insights into inhibitor design","volume":"7","author":"Wang","year":"2017","journal-title":"RSC Adv"},{"key":"2025050510564173500_ref56","doi-asserted-by":"publisher","first-page":"115024","DOI":"10.1016\/j.ejmech.2022.115024","article-title":"Pyrazolone derivatives as potent and selective small-molecule SIRT5 inhibitors","volume":"247","author":"Yao","year":"2023","journal-title":"Eur J Med Chem"}],"container-title":["Toxicology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxres\/article-pdf\/14\/3\/tfaf064\/63052342\/tfaf064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxres\/article-pdf\/14\/3\/tfaf064\/63052342\/tfaf064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T14:56:48Z","timestamp":1746457008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxres\/article\/doi\/10.1093\/toxres\/tfaf064\/8124772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/toxres\/tfaf064","relation":{},"ISSN":["2045-4538"],"issn-type":[{"value":"2045-4538","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,2]]},"article-number":"tfaf064"}}